Dementia Discovery Fund spinout LoQus23 Therapeutics announced the closing of a $15.4M seed fund, which the Cambridge-based company plans to use to develop drug candidates to target Huntington's disease and other triplet repeat disorders.
LoQus23 Therapeutics exits stealth with £11 5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ LoQus23 Therapeutics Ltd. ( LoQus23 ), a company discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat.